medigraphic.com
ISSN 1561-2937 (Print)

2019, Number 3

Next >>

Rev Cubana Cardiol Cir Cardiovasc 2019; 25 (3)

Cardiovascular manifestations of liver cirrhosis according to its etiology

Pérez BA, Hernández AE, Alfonso MOA, González PT, Samada SM, Hernández PJC, Puig FMJ, Ravelo LK

Language: Spanish
References: 48
Page:
PDF size: 443.02 Kb.


ABSTRACT

Introduction: Cirrhotic cardiomyopathy is a cardiac dysfunction, recently recognized as a clinical entity, present in patients with liver cirrhosis (CH), in the absence of another heart disease.
Method: An observational, descriptive, cross-sectional study was carried out with the objective of determining the cardiovascular manifestations of CH according to its etiology, in patients in liver transplant protocol in the CIMEQ, who underwent an electrocardiogram, echocardiogram, determination of the Oxygen arterial pressure and saturation thereof by oximetry.
Results: 95 cases were investigated, 55.7% women. The most frequent etiology of cirrhosis was viral (48.4%). 21.1% of cirrhotic patients were hypertensive. In alcoholic CH, the largest left ventricular end-diastolic diameters (LVDDD) were present (48.9 + 5.7 mm, p = 0.04), the lower E wave velocities (48.9 + 5.7 mm, p = 0.04), the higher wavelength A (72.2 + 16.1 cm/s, p = 0.03) and the highest values of E/e '(10.1 + 2.38, p = 0.04), followed by the viral CH, the cryptogenic and the autoimmune. These patients also had the highest QTc (426.9 + 17.3 ms, p = 0.16) and the lowest arterial oxygen pressure (79.6 + 12.3 mm hg, p = 0.01).
Conclusions: In the alcoholic CH, the electrocardiographic, echocardiographic and related alterations in the arterial oxygenation state show signs of diastolic dysfunction and greater compromise of cardiac function, which could be due to liver disease or the toxic effects of alcohol. Within the other etiologies, the viral ones were those that modified the variables studied the most and the autoimmune ones the least.


REFERENCES

  1. World Health Statistics. Monograph on the Internet. Ginebra: World Health Organization; 2011 [citado 13 Oct 2011]. Disponible en: https://apps.who.int/ infobase.

  2. Cuba. Ministerio de Salud Pública. Anuario estadístico de salud 2018. [sitio Disponible en: www.sld.cu/sitios/dne/].

  3. Poordad FF. Presentation and complications associated with cirrhosis of the liver. Curr Med Res Opin. 2015 May; 31(5):925-37.

  4. Kowalski HJ, Abelmann WH. Cardiac output at rest in Laenec’s cirrhosis. J Clin Invest. 1953; 32:1025-33.

  5. Moller S, Lee SS. Cirrhotic cardiomyopathy. J Hepatol 2018;69:958–60.

  6. Krowka MJ. Portopulmonary hypertension. SeminRespirCritCare Med 2012; 33:17–25.

  7. Voiosu AM, Daha IC, Voiosu TA, et al. Prevalence and impact on survival of hepatopulmonary syndrome and cirrhotic cardiomyopathy in a cohort of cirrhotic patients. Liver Int 2015; 35:2547–55.

  8. Karagiannakis DS, Papatheodoridis G, Vlachogiannakos J. Recent advances in cirrhotic cardiomyopathy. DigDisSci. 2015 May; 60(5):1141-51.

  9. Gassanov N, Caglayan E, Semmo N, Massenkeil G, Er F. Cirrhoticcardiomyopathy: a cardiologist's perspective. World J Gastroenterol. 2014 Nov 14; 20(42):15492-8.

  10. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl. 2011; 6: S44–S52.

  11. Radek P, Rudolf P, Martina V, Petr H. Heart failure in patients with liver cirrhosis. Coret Vasa 55 (2013) e391 –e396.

  12. Polavarapu N, D. Liver in cardiopulmonary disease. Best Practice & Research Clinical Gastroenterology 27 (2013) 497 –512.

  13. Johanne, Berg Thomas. The Etiology, Diagnosis and Prevention of Liver Cirrhosis.DtschArztebl Int. 2013 Feb; 110(6): 85–91.

  14. Raval Z, Harinstein ME, Skaro AI, Erdogan A, DeWolf AM, Shah SJ, et al. Cardiovascular risk assessment of the liver transplant candidate. J Am CollCardiol. 2011 Jul 12; 58(3):223-31.

  15. Iacovoni A, De Maria R, Gavazzi A. Alcoholiccardiomyopathy. J Cardiovasc Med (Hagerstown). 2011 Dec; 11(12):884-92.

  16. VanWagner LB, Serper M, Kang R, et al. Factoiors Associated With Major Adverse Cardiovascular Events After Liver Transplantation Among a National Sample. Am J Transplant 2016;16: 2684–94.

  17. Yasser MahrousFouad, ReemYehia. Hepato-cardiac disorders. World J Hepatol2014: January 27; 6(1): 41-54.

  18. Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, et al. Chronic HCV infection is a risk of atherosclerosis j. atherosclerosis.2012; 221: 496-502.

  19. Feigenbaum H, Armstrong W, Ryan T. Feigenbaum's Echocardiography, Eighth Edition.; Philadelphia : Wolters Kluwer, |2018. p. 363-462.

  20. García Fernández MA, Zamorano J, Azevedo J. Doppler tissue imaging echocardiography. Madrid: McGraw-Hill/Interamericana; 1997. pp. 23-45.

  21. Sonny A, Govindarajan SR, Jaber WA, Cywinski JB. Systolic heart failure after liver transplantation: Incidence, predictors, and outcome. Clin Transplant 2018;32: e13199.

  22. Chen Y, Chan Albert C, See- Ching Chan, Siu-Ho Chok, Sharr William, Fung James, et al. A detailed evaluation of cardiac function in cirrhotic patients and its alteration with or without liver transplantation. Journal of Cardiology 67 (2016) 140–146.

  23. Enache I, O Mammosser M, WoehlJaegle M L ,Habersetzer F, Di Marco P , Charloux A et al.Cirrhotic cardiomyopathy and hepatopulmonary syndrome: Prevalence and prognosis in a series of patients.Rev. Respiratory medicine. 2013. 107, 1031-1036:www.sciencedirect.com

  24. Gomes V, Filho M. Echocardiography in Chronic Liver Disease: Systematic Review. Arq Bras Cardiol. 2013; 100(4):376-385.

  25. Rodríguez Magallán A, Valencia Romero HS, Trinidad Altamirano J. Etiología y complicaciones de la cirrosis hepática en el Hospital Juárez de México.RevHospJua Mex.2008; 75(4):247-56.

  26. Escobar Suárez J. Repercusión de la capacidad de respuesta cardiovascular en la estabilidad hemodinámica y la aparición de complicaciones en trasplante hepático. Tesis para optar por el grado científico de Doctor en Medicina. Universidad de Barcelona. Departamento de cirugía. Barcelona, Julio 2013.

  27. Fajardo MH, Arce M, Medina Y, Esteva L, Osorio M. Comportamiento de la cirrosis hepática en el hospital "Arnaldo Milián Castro" de julio de 2007 a marzo de 2009. Medisur. 2010 [citado 10 Nov. 2012]; 8(4). Disponible en: http://medisur.sld.cu/index.php/medisur/article/view/1154/7179

  28. Safdar K, Schiff ER. Alcohol and Hepatitis C. Seminars in Liver Disease.2004; volume 24 (3): 305-10.

  29. Sagnelli E, Stroffolini T, Mele A, Almasio P, Coppola N, Ferrigno L, et al. The Importance of HCV on the Burden of Chronic Liver Disease in Italy: A Multicenter Prevalence Study of 9,997 Cases. Journal of Medical Virology. 2005; 75:522–527.

  30. Huertas Cuaresma J, Méndez Perles C, Medina Mirón M, González Gallardo M. Cirrosis hepática en el hospital clínico San Carlos. En: Piédrola G. Medicina Preventiva y Salud Pública. Madrid; 2007.p.1-17.

  31. Hernández P JC, Samada M, Abreu A, Ramos L, Lara E, González F, et al. Síndrome hepatopulmonar. Presentación de 1 caso y revisión. Rev cubana med.2005; v.44 n.1-2.

  32. Castellanos MI. La importancia de la desnutrición en el pronóstico del paciente con cirrosis hepática. Rev Cubana Alim Nutr. 2011; 21(S1): S1-84.

  33. Muratoti P, Czaja AJ, Muratori L. Genetic distinctions between autoimmune hepatitis in Italy and North America. World J Gastroenterol. 2005; 11:1862-6.

  34. Wiese S, Hove JD, Bendtsen F, Moller S.Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol 2014; 11:177–86

  35. García-Pagán JC, Calleja JL, Bañares R. Enfermedades hepáticas.GastroenterolHepatol. 2006; 29(Supl 3):99-111.

  36. Rodríguez O, Baldo R, Cardoso S. Consumo de alcohol: Alcoholismo y rasgos psicológicos de la personalidad. Rev Cubana Med Gen Integr [Revista en Internet] 2000 Jun. [citado 30 de junio de 2008]; 16(3): 255-259. Disponible en:http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S086421252000000300007&lng=es&nrm=iso

  37. Samada Suárez M. Factores pronósticos de supervivencia en pacientes con cirrosis hepática. Tesis para optar por el Grado Científico de Doctor en Ciencias Médicas evaluados para trasplante hepático. Instituto Superior de Ciencias Médicas de La Habana. CIMEQ 2008.

  38. Giraldo Montoya AM, Barraza Amador M, Villa Velásquez H, Martínez JW,García Castro G. Caracterización epidemiológica de pacientes con cirrosis en una consulta de gastroenterología en Pereira, Colombia, 2009-2012. Rev. Méd. Risaralda 2014; 20 (2):86-94.

  39. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34:2159–219.

  40. Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment PharmacolTher 2013; 37: 647-652

  41. Alberico L. Catapano, Ian Graham, Guy De Backer, Olov Wiklund M. John Chapman, Heinz Drexel, et al. Guía de la ESC/EAS sobre el manejo de las dislipemias. Rev Esp Cardiol. 2017;70(2): 115.e1-e64. Diponible en: ESC: www.escardio.org/guidelines.

  42. Yoo HY, Thuluvath PJ. The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation 2002; 74:1007–12.

  43. Jacobi J, Bircher N, Krinsley J, Agus M, Braithwaite SS, Deutschman C, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Crit Care Med. 2012; 40:3251–76.

  44. An J, Shim JH, Kim SO, Lee D, Kim KM, Lim YS, et al. Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study. Circulation. 2014 Oct 14;130(16):1353-62.Disponible en:10.1161/CIRCULATIONAHA.114.009278

  45. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatolo. 2002; 36:227–42.

  46. Gomes V, Filho M. Echocardiography in Chronic Liver Disease: Systematic Review. Arq Bras Cardiol. 2013; 100(4):376-385.

  47. Pozzi M, Redaelli E, Ratti L, Poli G, Guidi C, Milanese M, et al. Time-course of diastolic dysfunction in different stages of chronic HCV related liver diseases. Minerva GastroenterolDietol. 2005; 51(2):179-86.

  48. Castellanos Fernández MI, Rogel Marroquín BI, Rodríguez Martorell F, Arjona Rodríguez IA, Lazo del Vallin S. Disfunción cardiaca en la cirrosis hepática. Rev Cubana Med. 2014;53(2)




2020     |     www.medigraphic.com